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Background: Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. Elderly patients are under-
represented in Phase III clinical trials, and as a consequence the efficacy of adjuvant therapy in older patients with pancreatic
cancer is not clear. We aimed to assess the use and efficacy of adjuvant chemotherapy in older patients with pancreatic cancer.
Methods:We assessed a community cohort of 439 patients with a diagnosis of pancreatic ductal adenocarcinoma who underwent
operative resection in centres associated with the Australian Pancreatic Cancer Genome Initiative.
Results: The median age of the cohort was 67 years. Overall only 47% of all patients received adjuvant therapy. Patients who
received adjuvant chemotherapy were predominantly younger, had later stage disease, more lymph node involvement and more
evidence of perineural invasion than the group that did not receive adjuvant treatment. Overall, adjuvant chemotherapy was
associated with prolonged survival (median 22.1 vs 15.8 months; Po0.0001). Older patients (agedX70) were less likely to receive
adjuvant chemotherapy (51.5% vs 29.8%; Po0.0001). Older patients had a particularly poor outcome when adjuvant therapy was
not delivered (median survival¼ 13.1 months; HR 1.89, 95% CI: 1.27–2.78, P¼ 0.002).
Conclusion: Patients aged X70 are less likely to receive adjuvant therapy although it is associated with improved outcome.
Increased use of adjuvant therapy in older individuals is encouraged as they constitute a large proportion of patients with
pancreatic cancer.
Pancreatic cancer is the fourth leading cause of cancer death in
Western societies, with a 5-year survival rate of o5% (Jemal et al,
2008). Operative resection remains the primary treatment modality
and the only chance of cure (Yeo et al, 1997). Those who undergo
resection still only have a median survival of 14–20 months and a
5-year survival rate of B10% with surgery alone and up to 25%
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with adjuvant chemotherapy (Neoptolemos et al, 2001). Patterns of
disease recurrence and the rapid demise of a high proportion of
patients with pancreatic cancer even after complete surgical
resection suggests that occult metastatic disease is often present
at the time of surgery (Barugola et al, 2007; Schnelldorfer et al,
2008). Thus, it is clear that loco-regional therapies alone are usually
not curative and systemic therapies need to be considered in the
majority of patients following resection.
In pancreatic cancer, chemotherapy appears to be most effective
in the adjuvant setting. In 2001, ESPAC-1 compared 5-fluorouracil,
a pyrimidine analogue-based agent, to observation following
resection and showed that chemotherapy delayed time to
recurrence by 5.9 months and also improved overall survival
(19.7 vs 14.0 months; P¼ 0.0005) (Neoptolemos et al, 2001, 2004).
In addition, CONKO-001 independently showed that adjuvant
Gemcitabine, a nucleoside analogue, improved a 5-year survival of
10% after surgery alone to 20–25% (Oettle et al, 2007). Adjuvant
Gemcitabine, owing to its favourable toxicity profile, has become
the standard of care for this disease (Neoptolemos et al, 2010).
Approximately 60% of patients with pancreatic cancer are aged
65 and over (National Cancer Institute, 2010); however, patients
enrolled in ESPAC-1 and CONKO-001 had a younger median age
of 60 and 61, respectively (Neoptolemos et al, 2004; Oettle et al,
2007). It is increasingly recognised that elderly patients are under-
represented in cancer trials and that well-selected elderly patients
can undergo aggressive surgery for pancreatic cancer (Hutchins
et al, 1999; Lee et al, 2010). This is an important issue in an ageing
population as cancer is still a major cause of death in this age group
(Edwards et al, 2002). It remains unclear whether the use of
adjuvant chemotherapy in elderly patients with pancreatic cancer
is effective, and given that this question is unlikely to be examined
in a clinical trial, we assessed the efficacy of adjuvant therapy in a
large community cohort.
We show that patients with pancreatic cancer in the community
are older than patients included in Phase III clinical trials, and that
elderly patients are less likely to receive adjuvant chemotherapy;
yet it is well-tolerated and associated with improved outcome. This
highlights the need for greater efforts to offer older patients
adjuvant therapy and include them in clinical trials.
PATIENTS AND METHODS
Patients and data acquisition. Clinico-pathologic, treatment and
outcome data for a cohort of 439 patients with a diagnosis of
pancreatic ductal adenocarcinoma who underwent pancreatic
resection with curative intent (no macroscopic residual disease)
were accrued from 12 hospitals associated with the Australian
Pancreatic Cancer Genome Initiative between 1990 to 2011 (APGI;
www.pancreaticcancer.net.au) (Table 1). Ethical approval for the
study was obtained from the Human Research Ethics Committee at
each participating institution.
All cases underwent central pathology review by at least one
specialist pancreatic histopathologist (AJG, AC, JGK) who was
blinded to the diagnosis and clinical outcomes to verify the
diagnosis of pancreatic ductal adenocarcinoma and to define
histopathologic features in a standardized manner using a synoptic
report developed for the purpose (Gill et al, 2009). Tumours were
staged according to the AJCC Cancer Staging Manual 7th edition
2009 (Edge and Compton, 2010).
Clinico-pathologic information was acquired initially retro-
spectively, and became prospective in 2006. Data were extracted
from hospital notes (clinical history, preoperative imaging reports
such as computed tomography, magnetic resonance imaging,
ultrasound and endoscopic ultrasonography, surgeon’s operating
reports, anaesthesiologists reports and correspondence letters from
surgeon’s and medical oncologist’s consulting rooms). The date
and cause of death were obtained from Cancer Registries and
treating clinicians.
Statistical analysis. Overall survival was used as the primary end
point and was calculated from the date of diagnosis to the date of
death or last clinical follow-up. Univariate Kaplan–Meier analysis
of patient, tumour and treatment variables compared median
survival using the log-rank test. Variables assessed were sex, age,
tumour location, tumour size, lymph node status, stage, differ-
entiation, vascular invasion, perineural invasion, margin status,
treatment with adjuvant chemotherapy, palliative chemotherapy
and adjuvant radiotherapy. Factors associated with differential
survival on univariate analysis with a P-value o0.25, or with a
previously published association were included in Cox propor-
tional hazard multivariate analysis. Variables with a P-valueo0.05
were considered statistically significant. Chi-square and Fisher
exact tests were used to compare categorical variables and the
Student’s t-test to compare continuous variables for all analyses.
Statistical analysis was performed using Stata version 9.2 (Stata
Corp., College Station, TX, USA).
RESULTS
Patient cohort (all patients). The cohort of 439 patients consisted
of 230 males and 209 females. The mean age at diagnosis was 65.9,
with a median of 67 (range 28 to 87). Ninety-one patients (20.7%)
were alive at the censor date of 30 September 2011. Three hundred
and eighteen patients (72.5%) died of pancreatic cancer and 29
(6.6%) died of other causes. Twelve patients (2.8%) died within 30
days of surgery and 1 (0.2%) was lost to follow-up. Among those
who were still alive, the median follow-up was 22.3 months (range,
0.5–193 months). The median progression-free survival was 12.8
months and the overall survival was 18.1 months.
Detailed clinico-pathologic, treatment and outcome character-
istics of the cohort are presented in Table 1: 272 patients (62.0%)
had resections with clear margins defined as no tumour present at
transected surfaces (Chang et al, 2009)) and 289 (66.7%) had
lymph node metastasis. The majority (86.0%) had tumours of the
pancreatic head. Factors associated with improved outcome on
univariate analysis included tumours of the pancreatic head
(median survival 18.5 vs 12.8 months; P¼ 0.0008) compared with
body/tail tumours; tumour size 420mm (25.0 vs 16.6 months;
P¼ 0.0008); absence of margin involvement (22.1 vs 13.5 months;
Po0.0001); absence of lymph node metastases (19.7 vs 17.2
months; P¼ 0.025); absence of perineural invasion (25.4 vs
17.2 months; P¼ 0.01); absence of vascular space invasion (20.5 vs
16.4 months; P¼ 0.017) and use of adjuvant chemotherapy
(22.1 vs 15.8 months; Po0.0001; Table 2). There was no statistically
significant difference in survival between young patients (ageo70;
n¼ 261) and older patients (defined as patients aged 70 or over;
n¼ 178) overall (median survival: 20.2 vs 15.8 months; P¼ 0.085).
Multivariate analysis identified that age, tumour size, margin
status, perineural invasion, vascular space invasion and use of
adjuvant chemotherapy were independent prognostic factors
(Table 3A). The baseline characteristics of our cohort, excluding
age, were comparable to Phase III trials in resected pancreatic
cancer (Neoptolemos et al, 2004; Oettle et al, 2007).
A total of 205 patients (46.7%) received adjuvant therapy: 187
patients (42.7%) received adjuvant chemotherapy, whereas 21
(4.8%) received adjuvant radiotherapy and 32 (7.3%) received
chemoradiation. The majority of patients who received chemotherapy
received Gemcitabine (n¼ 145; 79.2%) and the remainder received
5-Flourouracil and/or platinum-based cytotoxics. The mean
number of cycles received was 5. Use of chemotherapy increased
significantly after 2001 when clinical trial data began to emerge
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Table 1. Baseline characteristics of entire cohort and dichotomized by age groups with univariate analysis
Entire cohort (N¼439)
Young cohort aged o70 years
(n¼261)
Elderly cohort aged X70 years
(n¼178)
Variables n (%)
Median OS
(months)
P-value
(log-rank) n (%)
Median OS
(months)
P-value
(log-rank) n (%)
Median OS
(months)
P-value
(log-rank) P-valuea
Mean age, years 65.9 59.57 75.2 0.085
Median 67
Range 28–87
Gender 0.006
Male 230 (52.4) 18.5 0.795 151 (57.9) 19.6 0.470 79 (44.4) 16.5 0.431
Female 209 (47.6) 17.8 110 (42.1) 22.1 99 (55.6) 15.6
Stage 0.008
1A 10 (2.3) 25.7 0.139 7 (2.7) 24.8 0.884 3 (1.7) 40.5 0.037
1B 21 (4.9) 18 (7.0) 3 (1.7)
2A 114 (26.4) 17.6 55 (21.4) 19.6 59 (33.7) 15.7
2B 287 (66.4) 177 (68.9) 110 (62.9)
Differentiation 0.457
Well 33 (8.9) 26.2 0.373 16 (7.4) 26.2 0.576 17 (10.9) 21.8 0.425
Moderate 238 (63.8) 17.5 139 (64.1) 20.2 99 (63.5) 13.3
Poor 102 (27.3) 18.1 62 (28.6) 19.6 40 (25.6) 16.0
Tumour location 0.299
Head 369 (86.0) 18.5 0.021 223 (87.5) 21.3 0.642 146 (83.9) 16.9 0.005
Body/tail 60 (14.0) 12.8 32 (12.5) 19.3 28 (16.1) 8.9
Tumour size (mm) 0.827
p20 103 (23.6) 25.0 0.001 62 (23.9) 27.5 0.049 41 (23.0) 24.4 0.005
420 334 (76.4) 16.6 197 (76.1) 19.4 137 (77.0) 12.8
Margins (0mm) 0.345
Clear 272 (62.0) 22.1 o0.0001 157 (60.2) 23.4 o0.0001 115 (64.6) 18.0 o0.0001
Involved 167 (38.0) 13.5 104 (39.8) 16.0 63 (35.4) 11.0
Lymph nodes 0.121
Negative 144 (33.3) 19.7 0.025 78 (30.4) 21.5 0.082 66 (37.5) 18.0 0.122
Positive 289 (66.7) 17.2 179 (69.6) 19.3 110 (62.5) 13.1
Perineural invasion 0.280
Negative 102 (23.6) 25.4 0.010 56 (21.8) 27.5 0.113 46 (26.3) 20.9 0.022
Positive 330 (76.4) 17.2 201 (78.2) 19.5 129 (73.7) 13.3
Vascular invasion 0.012
Negative 224 (52.1) 20.5 0.017 120 (47.1) 20.5 0.845 104 (59.4) 19.3 o0.0001
Positive 206 (47.9) 16.4 135 (52.9) 21.5 71 (40.6) 12.0
Radiotherapy 0.040
No adjuvant 416 (95.2) 18.1 0.752 243 (93.5) 19.7 0.830 173 (97.7) 15.9 0.452
Adjuvant 21 (4.8) 18.6 17 (6.5) 21.5 4 (2.3) 10.7
Adjuvant chemotherapy o0.0001
Adjuvant 187 (42.7) 22.1 o0.0001 134 (51.5) 22.5 0.085 53 (29.8) 21.8 0.003
No adjuvant 251 (57.3) 15.8 126 (48.5) 17.5 125 (70.2) 13.1
Palliative chemotherapy 0.002
No palliative therapy 314 (71.7) 16.5 0.74 188 (67.9) 18.5 0.266 126 (78.3) 13.3 0.582
Palliative therapy 124 (28.3) 21.3 89 (32.1) 21.5 35 (21.7) 21.1
Outcome
Pancreatic cancer death 318 (72.4) 182 (69.7) 136 (76.4) 0.124
Death – other causes 29 (6.6) 16 (6.1) 13 (7.3)
Alive 92 (21.0) 63 (24.1) 29 (16.3)
Median overall survival
(months)
18.1 20.2 15.8 0.085
Abbreviation: OS¼overall survival.
aComparison of variables between o70 cohort and X70 cohort.
Adjuvant therapy for pancreatic cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.722 315
Table 2. Comparison between adjuvant chemotherapy group and no adjuvant chemotherapy group in each cohort
Entire cohort (N¼439) Cohort aged o70 years (n¼261) Cohort aged X70 years (n¼178)
Adjuvant
chemo-
therapy
(n¼187)
No adjuvant
chemo-
therapy
(n¼251)
Adjuvant
chemo-
therapy
(n¼134)
No
adjuvant
chemo-
therapy
(n¼126)
Adjuvant
chemo-
therapy
(n¼53)
No adjuvant
chemo-
therapy
(n¼125)
Variables n (%) n (%) P-valuea n (%) n (%) P-valuea n (%) n (%) P-valuea
Mean age, years 63.4 67.8 o0.0001 59.22 59.88 0.504 73.87 75.77 o0.001
Gender
Male 107 (57.2) 122 (48.6) 0.08 79 (59.0) 71 (56.4) 0.671 28 (52.8) 51 (40.8) 0.140
Female 80 (42.8) 129 (51.4) 55 (41.0) 55 (43.7) 25 (47.2) 74 (59.2)
Stage
1A 1 (0.5) 9 (3.7) 0.04 1 (0.8) 6 (4.8) 0.013 0 (0.0) 3 (2.5) 0.013
1B 7 (3.8) 14 (5.7) 4 (3.0) 14 (11.3) 3 (5.7) 0 (0.0)
2A 41 (22.2) 73 (29.7) 28 (21.1) 27 (21.8) 13 (24.5) 46 (37.7)
2B 136 (73.5) 150 (61.0) 99 (74.4) 77 (62.1) 37 (69.8) 73 (59.8)
Differentiation
Well 10 (7.2) 23 (9.8) 0.72 6 (6.0) 10 (8.6) 0.738 4 (10.3) 13 (11.1) 0.888
Moderate 90 (64.7) 148 (63.2) 64 (64.0) 75 (64.1) 26 (66.7) 73 (62.4)
Poor 39 (28.1) 63 (26.9) 30 (30.0) 32 (27.4) 9 (23.1) 31 (26.5)
Tumour location
Head 159 (88.8) 209 (83.9) 0.16 116 (89.2) 106 (85.5) 0.368 43 (87.8) 103 (82.4) 0.387
Body/tail 20 (11.2) 40 (16.1) 14 (10.8) 18 (14.5) 6 (12.2) 22 (17.6)
Tumour size (mm)
p20 44 (23.7) 59 (23.6) 0.99 34 (25.6) 28 (22.4) 0.552 10 (18.9) 31 (24.8) 0.390
420 142 (76.3) 191 (76.4) 99 (74.4) 97 (77.6) 43 (81.1) 94 (75.2)
Margins (0mm)
Clear 112 (59.9) 159 (63.3) 0.49 79 (59.0) 77 (61.1) 0.723 33 (62.3) 82 (65.6) 0.670
Involved 75 (40.1) 92 (36.7) 55 (41.0) 49 (38.9) 20 (37.7) 43 (34.4)
Lymph nodes
Negative 49 (26.3) 95 (38.6) 0.008 33 (24.8) 45 (36.6) 0.041 16 (30.2) 50 (40.7) 0.188
Positive 137 (73.7) 151 (61.3) 100 (75.2) 78 (63.4) 37 (69.8) 73 (59.4)
Perineural invasion
Negative 32 (17.4) 70 (28.3) 0.008 21 (15.9) 35 (28.2) 0.017 11 (21.2) 35 (28.5) 0.316
Positive 152 (83.5) 177 (71.7) 111 (84.1) 89 (71.8) 41 (78.9) 88 (71.5)
Vascular invasion
Negative 88 (47.8) 136 (55.5) 0.12 57 (43.2) 63 (51.6) 0.177 31 (59.6) 73 (59.4) 0.974
Positive 96 (52.2) 109 (44.4) 75 (56.8) 59 (48.4) 21 (40.4) 50 (40.7)
Palliative chemotherapy
No palliative 137 (73.3) 177 (70.5) 0.528 91 (67.9) 81 (64.3) 0.537 46 (86.8) 96 (76.8) 0.129
Palliative 50 (26.7) 74 (29.5) 43 (32.1) 45 (35.7) 7 (13.2) 29 (23.2)
Radiotherapy
No adjuvant 169 (90.9) 247 (98.4) o0.00001 119 (88.8) 124 (98.4) 0.022 50 (96.2) 123 (98.4) 0.012
Adjuvant 17 (9.1) 4 (1.6) 15 (11.2) 2 (1.6) 2 (3.9) 2 (1.6)
Outcome
Pancreatic cancer death 112 (59.8) 206 (82.1) o0.0001 83 (61.9) 99 (78.6) 0.003 29 (54.7) 107 (85.6) o0.0001
Death – other causes 8 (4.3) 21 (8.4) 5 (3.7) 11 (8.7) 3 (5.7) 10 (8.0)
Alive 67 (35.8) 24 (9.6) 46 (34.3) 16 (12.7) 21 (39.6) 8 (6.4)
Median overall survival (months) 22.1 15.8 o0.0001 22.5 17.5 0.085 21.8 13.1 0.003
aComparison of variables between adjuvant chemotherapy and no adjuvant chemotherapy within each cohort.
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supporting its use. Pre-2001, only 19.1% of patients received
adjuvant chemotherapy compared with 56.5% after 2001
(Po0.0001). In addition, the use of Gemcitabine increased post
2001 (8.0% vs 47.8%; Po0.0001) (Figure 1A).
Patients that receive adjuvant chemotherapy have poor
prognostic factors. To further clarify the role of adjuvant
chemotherapy, patients were stratified into two groups of ‘adjuvant
chemotherapy’ and ‘no adjuvant chemotherapy’. Patient, tumour
and treatment characteristics of the two groups were compared
(Table 2). The group that received adjuvant chemotherapy had
more poor prognostic factors including more advanced stage (stage
2B; 73.5% vs 61.0%; P¼ 0.04), more tumours with positive lymph
nodes (73.7% vs 61.3%; P¼ 0.008) and a higher prevalence of
perineural invasion (83.5% vs 71.7%; P¼ 0.008). In addition, the
group that had adjuvant chemotherapy was significantly younger
(63.4 vs 67.8 years; P o0.0001). Despite the constellation of
adverse features, the group that received adjuvant chemotherapy
had a significantly better median survival (Figure 1B).
Older patients that do not receive adjuvant therapy have a poor
prognosis. To investigate the relationship between age and
outcome, patients were stratified into two groups of ‘cohort
younger than 70’ and ‘cohort 70 or older’. Sex, tumour pathological
characteristics and treatment (adjuvant chemotherapy, palliative
chemotherapy and radiotherapy) were compared between the two
Table 3. Final multivariate model of overall survival for entire cohort,
elderly cohort and young patient cohort
Variables Hazard ratio (95% CI) P-value
(A) Entire cohort
Age, X70 years 1.35 (1.07–1.70) 0.01
Tumour size, 420mm 1.43 (1.10–1.85) 0.007
Margins, involved 1.69 (1.35–2.12) o0.0001
Perineural invasion, positive 1.33 (1.02–1.72) 0.033
Vascular invasion, positive 1.37 (1.09–1.71) 0.007
Adjuvant chemotherapy, none 1.38 (1.21–1.50) o0.0001
(B) Older cohort (age X70 years)
Tumour location, head 1.37 (1.03–1.59) 0.037
Margins, involved 1.98 (1.40–2.79) o0.0001
Vascular invasion, positive 2.79 (1.60–3.24) o0.0001
Adjuvant chemotherapy, none 1.47 (1.21–1.64) 0.002
(C) Young cohort (age o70 years)
Margins, involved 1.81 (1.36–2.42) o0.0001
Adjuvant chemotherapy, none 1.35 (1.02–1.79) 0.035
Abbreviation: CI¼ confidence interval.
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Figure 1. (A) Use of adjuvant chemotherapy before and after publication of ESPAC-1 in 2001. (B) Kaplan–Meier survival curves of the entire cohort
stratified by use of adjuvant chemotherapy (N¼ 439). (C) Kaplan–Meier survival curves of sub-groups (o70 andX70) stratified by use of adjuvant
chemotherapy.
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groups. A total of 178 patients (40.5%) were X70 years old. The
younger cohort (o70) had more poor prognostic factors; more
males (57.9% vs 44.4%; P¼ 0.006), more advanced stage (stage 2B;
68.1% vs 62.9%; P¼ 0.008) and more patients with evidence of
vascular space invasion (52.1% vs 40.6%; P¼ 0.012). Adjuvant
chemotherapy (51.5% vs 29.8%; Po0.0001), palliative chemotherapy
(33.8% vs 20.2%; P¼ 0.002) and adjuvant chemoradiation
(10.0% vs 3.4%; P¼ 0.009) were all less frequently administered in
the older (X70) patient subgroup (Table 1). The 30-day mortality
did not differ (1.9% vs 4.0%; P¼ 0.187) and the mean number of
cycles of chemotherapy received was the same in the two sub-groups
(5.2 vs 5.2; P¼ 0.922). The cause of death in patients agedX70 was
predominantly pancreatic cancer (76.4%) and did not significantly
differ from young patients. Only 7.3% of pancreatic cancer patients
aged X70 died of causes other than cancer, again no different to
younger patients (7.3% vs 6.1%; P¼ 0.124).
Not receiving adjuvant chemotherapy was an independent poor
prognostic factor in the older population (HR 1.89, 95% CI:
1.27–2.78, P¼ 0.002) (Table 3B). Figure 1C shows the cohort divided
into four groups based on age (o70 and X70) and use of adjuvant
chemotherapy (adj and no adj). Patients aged X70 who did not
receive adjuvant chemotherapy had an extremely poor outcome
with a median survival of only 13.1 months despite favourable
clinico-pathologic features, whereas elderly patients who received
adjuvant chemotherapy had an outcome similar to young patients
(21.8 vs 22.5; P¼ 0.576) (Table 2; Figure 1C). In addition, patients
aged X70 who did not receive adjuvant chemotherapy were less
likely to receive palliative chemotherapy than the corresponding
group of patients aged o70 (23.2% vs 35.7%; P¼ 0.03); however,
palliative chemotherapy had no effect on survival in either group
on univariate or multivariate analysis.
DISCUSSION
Adjuvant chemotherapy improves outcomes for patients with
pancreatic cancer in the community and supports clinical trial data
even though clinical trials selectively recruit patients (Neoptolemos
et al, 2004; Oettle et al, 2007). Patients in the community are older
than patients in clinical trials, and older patients are less likely to
receive adjuvant therapy, although data from this study suggest
that it is associated with improved survival to a similar, if not
greater degree as it is for younger patients.
Recently, several studies have examined the role of palliative
chemotherapy in advanced pancreatic cancer showing that
Gemcitabine in elderly patients is as well-tolerated and equally as
effective as in younger patients (Marechal et al, 2008; Hentic et al,
2011). With regard to adjuvant therapy, a recent population study
suggested that adjuvant chemotherapy was less frequently
administered to older patients with pancreatic cancer (Davila
et al, 2009). Previous studies focusing on colon and breast cancer
as well as a single institution study in pancreatic cancer suggest
that older patients are less likely to receive adjuvant treatment in
many different cancer types, although it is associated with
improved outcomes (Potosky et al, 2002; Bouchardy et al, 2003;
Barbas et al, 2012).
In older patients with cancer, reluctance to administer adjuvant
treatment may be based on the perception that they have an
increased risk of a non-cancer-related cause of death and therefore
the overall benefit of adjuvant therapy is limited. Our study
highlights that this is not the case and the predominant cause of
death in older patients is still cancer, and not different to a younger
population. The mean number of cycles of chemotherapy received
by elderly patients was the same as young patients suggesting
that once adjuvant treatment was commenced, older patients
were equally likely to complete treatment. Importantly, adjuvant
chemotherapy is the only actionable variable associated with
improved survival in older patients. Unless further studies emerge
suggesting that adjuvant chemotherapy provides unacceptable
toxicity in the elderly, efforts to increase the use of adjuvant
chemotherapy in older patients may improve overall outcomes,
particularly in the setting of ageing populations.
We acknowledge that there are limitations to this study and that
a prospective study in older patients would better clarify the role of
adjuvant chemotherapy. Such a study may be difficult to conduct
given the proven role of adjuvant chemotherapy and unlikely to be
undertaken. As the study did not collect preferences data, it is not
possible to comment on the reasons that patients did not receive
adjuvant treatments. In addition, we cannot be certain that older
patients were not more likely to be of a lower performance status
following surgery. However, the study found that the post-
operative stay following surgery was similar (12 days) as was the
post-operative mortality rate. In addition, the rates of adjuvant
chemotherapy use have increased since 2001 suggesting that an
increase in uptake is possible and may be independent of patient
characteristics.
In conclusion, pancreatic cancer is predominantly a cancer of
older age groups and therefore is not entirely reflective of patients
who were included in published Phase 3 clinical trials. In this
study, adjuvant chemotherapy was independently associated with
improved outcome in all patients. The benefit of 8.7 months with
adjuvant chemotherapy in older patients is clinically significant;
however, the utilisation rate of adjuvant treatments is markedly
lower than in young patients despite similar clinico-pathologic
features. Moreover, older patients who did receive adjuvant
chemotherapy were equally likely to complete treatment. Advan-
cing age alone should not preclude the use of adjuvant
chemotherapy in this highly lethal disease.
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